Baseline Patient Characteristics, Comorbidities, Prior Medication Use, and Reasons for Dupilumab Initiation in Adult Patients in Russia With Atopic Dermatitis: Real-World Insights Into the GLOBOSTAD Multinational Prospective Observational Study

28.11.2023

82 0

ФИО: Daria S. Fomina

Соавторы: Daria S. Fomina1,2,3, Konstantin Raznatovsky4, Natalia Makhneva5, Jiangming Wu6, Marius Ardeleanu7, Kwinten Bosman8

Направление: Дерматология

Название учреждения: 1City Clinical Hospital No. 52, Moscow, Russian Federation; 2I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation, Moscow, Russian Federation; 3Astana Medical University, Kazakstan; 4North-Western State Medical University, Saint- Petersburg, Russian Federation; 5Medical Center Stels, Moscow, Russian Federation; 6Sanofi, Bridgewater, NJ, USA; 7Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA; 8Sanofi, Amsterdam, Netherlands

Страна: Russia

Город: Moscow

Телефон: +7 (916) 597-18-06

Почта: daria.s.fomina@gmail.com

Baseline Patient Characteristics, Comorbidities, Prior Medication Use, and Reasons for Dupilumab Initiation in Adult Patients in Russia With Atopic Dermatitis: Real-World Insights Into the GLOBOSTAD Multinational Prospective Observational Study

Daria S. Fomina^1,2,3, Konstantin Raznatovsky⁴, Natalia Makhneva⁵, Jiangming Wu⁶, Marius Ardeleanu⁷, Kwinten Bosman⁸

¹City Clinical Hospital No. 52, Moscow, Russian Federation; ²I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation, Moscow, Russian Federation; ³Astana Medical University, Kazakstan; ⁴North-Western State Medical University, Saint-Petersburg, Russian Federation; ⁵Medical Center Stels, Moscow, Russian Federation; ⁶Sanofi, Bridgewater, NJ, USA; ⁷Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA; ⁸Sanofi, Amsterdam, Netherlands

Comprehensive real-world data on patients with moderate-to-severe atopic dermatitis (AD) receiving novel systemic treatments in Russia are limited. This analysis reports demographics, comorbidities and prior medication use at baseline in patients with moderate-to-severe AD patients

in Russia from the GLOBOSTAD registry. This 5-year, international, non-interventional study (GLOBOSTAD; NCT03992417) included patients aged ≥12 years with moderate-to-severe AD who initiated dupilumab treatment based on country-specific prescribing criteria. Data reported are for the population at baseline (data cut-off: July 2023).

A total of 46 Russian patients enrolled in the study, 69.6% were 18-39 years old and 30.4% were 40–64 years old, with a mean (standard deviation) age of 33.7 (11.4) years. At enrollment, 93.5% of patients had a previous history of type 2 inflammatory comorbidities, consisting mainly of

food allergies (82.6%), allergic rhinitis (65.2%), asthma (65.2%), and allergic conjunctivitis (69.6%). For a total of 45.7% of patients, the use of systemic treatments in the form of non-steroidal immunosuppressants (8.7%) and corticosteroids (39.1%) were reported for treating AD within the past 12 months before enrollment. While for 91.3% of patients, the use of non-systemic treatment in the form of topical corticosteroids (69.6%) and topical calcineurin inhibitors (13%) were reported for treating AD within the past 12 months before enrollment. The reasons for dupilumab treatment initiation were previous treatment failure (84.8%), AD exacerbation (6.5%), or initiation as maintenance treatment (8.7%).

Type 2 inflammatory comorbidities were present in nearly all of the patients enrolled in Russia in the GLOBOSTAD observational study. Most of the patients had used systemic and/or non-systemic AD treatments in the 12 months preceding dupilumab initiation. In most patients,

dupilumab treatment was initiated due to previous treatment failure. These baseline demographics are consistent with the overall GLOBOSTAD baseline demographics[1].

References

1. Calzavara-Pinton P., et al. Adv Ther (2023).

Acknowledgments and funding sources

Research sponsored by Sanofi and Regeneron Pharmaceuticals Inc. ClinicalTrials.gov Identifier: NCT03992417. Medical writing/editorial assistance was provided by Mark C. Howell, Jr., PhD, of Excerpta Medica, and was funded by Sanofi and Regeneron Pharmaceuticals Inc., according to the Good Publication Practice guideline.

Disclosures

DF: CSL Behring, Novartis, Sanofi, Shire – honoraria. KR: Sanofi, Abbvie, Galleria, LeoPharma, Novartis, Eli Lilly, Janssen – speaker. NM: AbbVie, Lilly, Janssen, LEO Pharma, Novartis, Sanofi, Galderma, Amgen, Pfizer, Sanofi – speaker; Sanofi – investigator. JW, KB: Sanofi – employees, may hold stock and/or stock options in the company. AM: Regeneron Pharmaceuticals, Inc. – employee and shareholder.